Skip to main content
Premium Trial:

Request an Annual Quote

Silicon Genetics Licenses Enterprise-Wide Expression Platform to AstraZeneca

SAN FRANCISCO, Jan. 15 - Silicon Genetics has licensed its enterprise gene-expression analysis platform to AstraZeneca, the company said on Tuesday.

 

The one-year license includes Silicon Genetics' GeneSpring, GeNet, and Script Editor software.

 

Financial details of the agreement were not disclosed, though Saeid Akhtari, chief operating officer of Silicon Genetics, called it "our biggest deal to date."

 

Akhtari said it is the first deal for Silicon Genetics in which a client licensed all of the enterprise products in a single agreement. Usually, pharmaceutical companies will first try out single aspects of an enterprise system under pilot programs.

 

"AstraZeneca expects to benefit from broader access to Silicon Genetics' informatics technology," said Kenneth Fasman, global head of R&D informatics at AstraZeneca.

 

Silicon Genetics expects to close two more enterprise system deals with new customers within the first quarter of this year, said Akhtari.

 

"This is the year of the enterprise [system]", he predicts. "We see a trend toward a global deployment of this technology."

 

Last September, Silicon Genetics and Optimal Design entered into a distribution agreement under which Silicon Genetics will market Optimal Design's ArrayMiner technology worldwide for use with Silicon's GeneSpring technology.

 

GeneSpring, a desktop gene-expression analysis software for microarray experiments, accepts data from array/scanner image analysis programs, other databases, spreadsheets, URLs, as well as UniGene, GenBank, and LocusLink databases. Silicon Genetics, meanwhile, released version 4.0 of its technology in April.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more